Teva Pharmaceutical Industries' (TEVA) Teva Pharmaceuticals US affiliate said Monday that the US Food and Drug Administration has approved at-home use of Igalmi sublingual film to treat agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders in adults.
The company said the approval makes Igalmi the first FDA-approved treatment for the disorders that can be used at home.
Agitation associated with schizophrenia, schizoaffective disorder, or bipolar I or II disorders affects 25% to 40% of patients with those conditions, Teva said, adding that up to 21% of cases can result in an emergency department visit or hospitalization.
Teva owns Igalmi as part of its October acquisition of BioXcel Therapeutics' assets.
Comments